TG Therapeutics Inc
TGTX29.230USD
-5.790-16.53%
交易中 （美東）報價延遲15分鐘
4.62B總市值
118.09本益比TTM
關於 TG Therapeutics Inc 公司
TG Therapeutics, Inc. 是一家完全整合的商業階段生物製藥公司。該公司專注於收購、開發和商業化 B 細胞疾病的新型治療方法。其臨牀候選藥物包括 Ublituximab（抗 CD20 mAb）、TG-1701（BTK 抑制劑）和 TG-1801（抗 CD47/CD19 雙特異性 mAb）。BRIUMVI 是一種抗 CD20 單克隆抗體，用於治療 RMS，包括臨牀孤立綜合徵、復發緩解性疾病和活動性繼發進展性疾病。TG-1701 是一種新型口服共價結合的布魯頓酪氨酸激酶 (BTK) 抑制劑，在體外激酶篩選中表現出對 BTK 的選擇性。TG-1801 是一種雙特異性 CD47 和 CD19 抗體。這是一種針對 CD19（一種在 B 細胞惡性腫瘤中表達的 B 細胞特異性市場）和 CD47 的療法。它還評估互補產品、技術和公司，以尋找許可、合作、收購和/或投資機會。
公司簡介
公司代碼TGTX
公司名稱TG Therapeutics Inc
上市日期Dec 14, 1995
CEOMr. Michael S. Weiss, J.D.
員工數量338
證券類型Ordinary Share
年結日Dec 14
公司地址3020 Carrington Mill Blvd., Suite 475
城市MORRISVILLE
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編27560-5435
電話18775758489
網址https://www.tgtherapeutics.com/
公司代碼TGTX
上市日期Dec 14, 1995
CEOMr. Michael S. Weiss, J.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
13.82M
--
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
600.61K
-19.72%
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
+5.56%
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
228.82K
+2.11%
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
222.89K
+10.63%
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
+8.27%
Dr. Sagar Lonial
Dr. Sagar Lonial
Independent Director
Independent Director
114.91K
+14.69%
名稱
名稱/職務
職務
持股
持股變動
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
13.82M
--
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
600.61K
-19.72%
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
+5.56%
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
228.82K
+2.11%
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
222.89K
+10.63%
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
+8.27%
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2025Q1
FY2024
業務USD
名稱
營收
佔比
Total product revenue, net
119.66M
99.01%
Royalty Revenue
605.00K
0.50%
Other Revenue
558.00K
0.46%
License Revenue
38.00K
0.03%
Milestone Revenue
0.00
0.00%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
Total product revenue, net
119.66M
99.01%
Royalty Revenue
605.00K
0.50%
Other Revenue
558.00K
0.46%
License Revenue
38.00K
0.03%
Milestone Revenue
0.00
0.00%
股東統計
更新時間: 5月16日 週五
更新時間: 5月16日 週五
持股股東
股東類型
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
12.11%
The Vanguard Group, Inc.
9.81%
Weiss (Michael S)
8.71%
State Street Global Advisors (US)
4.68%
Geode Capital Management, L.L.C.
2.07%
Other
62.63%
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
12.11%
The Vanguard Group, Inc.
9.81%
Weiss (Michael S)
8.71%
State Street Global Advisors (US)
4.68%
Geode Capital Management, L.L.C.
2.07%
Other
62.63%
股東類型
持股股東
佔比
Investment Advisor
35.59%
Investment Advisor/Hedge Fund
16.95%
Individual Investor
9.74%
Hedge Fund
4.94%
Research Firm
3.73%
Pension Fund
1.23%
Bank and Trust
0.41%
Sovereign Wealth Fund
0.25%
Family Office
0.13%
Other
27.03%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
691
115.81M
72.94%
-20.80M
2025Q1
704
116.82M
73.80%
-25.76M
2024Q4
657
113.87M
72.65%
-36.14M
2024Q3
598
117.83M
76.11%
-20.28M
2024Q2
544
109.58M
70.90%
-28.91M
2024Q1
535
105.41M
68.45%
-29.01M
2023Q4
542
104.64M
69.13%
-36.73M
2023Q3
552
104.67M
69.33%
-30.54M
2023Q2
543
102.45M
68.58%
-35.33M
2023Q1
550
108.72M
74.29%
-22.90M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BlackRock Institutional Trust Company, N.A.
19.22M
12.11%
-465.28K
-2.36%
Mar 31, 2025
The Vanguard Group, Inc.
15.57M
9.81%
+8.03K
+0.05%
Mar 31, 2025
Weiss (Michael S)
13.82M
8.71%
--
--
Apr 14, 2025
State Street Global Advisors (US)
7.43M
4.68%
-1.77M
-19.20%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.28M
2.07%
+89.06K
+2.79%
Mar 31, 2025
Soleus Capital Management, L.P.
2.85M
1.79%
+165.46K
+6.17%
Mar 31, 2025
ClearBridge Investments, LLC
2.64M
1.67%
+809.33K
+44.10%
Mar 31, 2025
Pictet Asset Management Ltd.
2.40M
1.51%
-396.75K
-14.20%
Mar 31, 2025
Fidelity Management & Research Company LLC
1.74M
1.1%
+710.43K
+68.88%
Mar 31, 2025
Hood River Capital Management LLC
1.56M
0.98%
+101.17K
+6.95%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Invesco S&P SmallCap Health Care ETF
3.49%
Invesco Biotechnology & Genome ETF
2.71%
Virtus LifeSci Biotech Products ETF
1.86%
SPDR S&P Biotech ETF
1.72%
Invesco S&P SmallCap 600 Pure Growth ETF
1.69%
Direxion Daily S&P Biotech Bull 3X Shares
0.98%
Invesco S&P SmallCap Momentum ETF
0.95%
SPDR S&P 600 Small Cap Growth ETF
0.71%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.71%
First Trust NASDAQ Pharmaceuticals ETF
0.67%
查看更多
Invesco S&P SmallCap Health Care ETF
佔比3.49%
Invesco Biotechnology & Genome ETF
佔比2.71%
Virtus LifeSci Biotech Products ETF
佔比1.86%
SPDR S&P Biotech ETF
佔比1.72%
Invesco S&P SmallCap 600 Pure Growth ETF
佔比1.69%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.98%
Invesco S&P SmallCap Momentum ETF
佔比0.95%
SPDR S&P 600 Small Cap Growth ETF
佔比0.71%
Vanguard S&P Small-Cap 600 Growth Index Fund
佔比0.71%
First Trust NASDAQ Pharmaceuticals ETF
佔比0.67%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
